Best Practices in Metastatic Colorectal Cancer

Slides:



Advertisements
Similar presentations
Part 2 Colorectal Cancer Thursday, July 26, :30 PM – 8:30 PM ET RTP TV: Emerging Treatment Strategies in Colorectal Cancer.
Advertisements

Managing the patients experience of radical surgery with HIPEC for stage 4 colorectal disease Jackie Rodger Lead Colorectal Nurse Specialist Carol Baird.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
The Nurse View: Management of Pancreatic Cancer
Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
The Current Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer.
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
Perspectives on Triple-Negative Breast Cancer
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Managing the Patient With Tuberous Sclerosis Complex
What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC
The Nurse View.
Glaucoma Progression.
New Patient Journeys in Non-small cell lung cancer
The Nurse View.
Introduction to Checkpoint Inhibitors
Patient 1: 53-Year-Old Man With CVD Risk Factors
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Medication Nonadherence in Gout
The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer
Colorectal Cancer: Current “Standard” Uses for Molecular Testing
How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients
The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.
Optimizing Outcomes in the Management of GIST
Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.
Program Goals Introduction Case 1: A 44-Year-Old Woman.
Clinical Considerations in Evidence-based Management of GIST
Fit for treatment Confirmed mCRC Request RAS Yes Liver only disease?
Tailoring Hemophilia Prophylaxis Therapy
Counseling Patients About Germline BRCA Mutations
Optimizing Management of Advanced Bladder Cancer
Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.
The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.
From Symptom Management to Communication in Advanced GI Cancers
Management of Adolescents With Seizures
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.
Personalized Therapy in Relapsed or Refractory CLL
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
The Road to Quality Improvement in HER2-Positive Breast Cancer
Cancer-Associated Thrombosis
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Management of Advanced Pancreatic Adenocarcinoma
Patient-Centered Management in Advanced Non-Small Cell Lung Cancer
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Program Goal. Program Goal Disclaimer Overview.
Contemporary Considerations in Biomarker-Guided Therapy
Prostacyclin Pathway Agents in Action
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
1Cancer Research UK, Glasgow, United Kingdom
Issues in Patients With Severe Epilepsy
What Is Acute Intermittent Porphyria? Why AIP Is Often Undiagnosed or Misdiagnosed.
Tailoring Therapy in the Newly Diagnosed Patient With CLL
Clinical Considerations in Evidence-based Management of GIST
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?
The Nurse View.
Understanding the Expanding Armamentarium for GIST
Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS.
Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.
Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.
A Fresh Perspective on Hypoactive Sexual Desire Disorder
Presentation transcript:

Best Practices in Metastatic Colorectal Cancer

Learning Objectives

Colorectal Cancer Overview

Case 1 JM, an 86-year-old Man With mCRC in Liver and Lung

Case 1 Therapy

Regorafenib

Regorafenib Adverse Effects

Nursing Interventions Regorafenib

Patient Education Regorafenib

Case 2 RP, A 42-year-old Woman

Case 2 Surgery

Case 2 Medical Therapy Options

Nursing Interventions Bevacizumab

Ziv-aflibercept

Case 2 Ziv-aflibercept Option

Nursing Interventions Ziv-aflibercept

Summary

Abbreviations

References

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.